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Within the last twenty years the view on reactive oxygen species (ROS) has changed; they are no longer
only considered to be harmful but also necessary for cellular communication and homeostasis in dif-
ferent organisms ranging from bacteria to mammals. In the latter, ROS were shown to modulate diverse
physiological processes including the regulation of growth factor signaling, the hypoxic response, in-
ﬂammation and the immune response. During the last 60–100 years the life style, at least in the Western
world, has changed enormously. This became obvious with an increase in caloric intake, decreased en-
ergy expenditure as well as the appearance of alcoholism and smoking; These changes were shown to
contribute to generation of ROS which are, at least in part, associated with the occurrence of several
chronic diseases like adiposity, atherosclerosis, type II diabetes, and cancer. In this review we discuss
aspects and problems on the role of intracellular ROS formation and nutrition with the link to diseases
and their problematic therapeutical issues.
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The research within the last twenty years on chemically re-
active molecules containing oxygen, commonly called reactive
oxygen species (ROS), has shown that these molecules are im-
portant for cellular communication and homeostasis in different
organisms ranging from bacteria to mammals. Thereby, ROS were
shown to modulate diverse physiological processes including the
regulation of growth factor signaling, the hypoxic response, in-
ﬂammation and the immune response in mammalian cells. ROS
are often simply called “free radicals” because their majority is
characterized by at least one unpaired electron in their outer or-
bitals; however, peroxides like hydrogen peroxide may also give
rise to the formation of oxygen radicals and are therefore also
considered as ROS. Frequently the incomplete reduction of oxygen
by one electron producing superoxide anion (O2
·−) is the ﬁrst step
for the formation of most other ROS [1,2].
The action of ROS is usually balanced by the antioxidative ca-
pacity of a cell or organism and a disturbance of this balance in
favor of a prooxidant state is commonly referred to as oxidative
stress. Oxidative stress is usually coupled to harmful effects due to
the primary chemical reactions of ROS with lipids and proteins. In
this respect, diseases frequently associated with a Western life-
style and nutritional regime like type II diabetes, cardiovascular
diseases or cancer were found to be associated with a deregulated
ROS formation [3–7]. Hence, it appears to be of special interest
that production of ROS due to nutrition may affect signaling
pathways and the pathogenesis of these diseases. In the current
review we aim to summarize some aspects on the role of ROS,
nutrition, intracellular ROS formation, and the link to diseases.Fig. 1. ROS generation in cells. ROS can be generated in response to various stimuli
among them diets or radiation which is supported by the action(s) of enzyme
(s) located in different intracellular compartments. ETC, electron transport chain;2. Cellular sources of ROS
A number of studies within the last decade indicated that
overnutrition-induced ROS formation and oxidative stress con-
tribute to the development of metabolic disorders, in particular to
insulin resistance, as well as to cardiovascular diseases, and cancer
[8–12].
In mammalian cells ROS can be generated in different cellular
compartments such as membranes, cytoplasm, mitochondria, en-
doplasmic reticulum (ER), lysosomes, and peroxisomes (Fig.1). In
the following we will give only a short summary because the role
of each compartment in ROS formation has been discussed else-
where in excellent detail [13].
2.1. Plasma membranes and ROS production
The prototypic NADPH oxidase was found in phagocytes loca-
lized in the plasma membrane and phagosomes [14]. It is com-
posed of gp91phox and the smaller subunit p22phox forming the
ﬂavocytochrome b558 [15,16] which is the catalytic core of the
NADPH oxidase generating O2
·−. Several homologs of gp91phox –now termed NOX2-named NOX1-5, and the more distantly related
DUOX1/2 (dual oxidases) were found [17–19]. NOX2 is mainly
expressed in polymorphonuclear cells, macrophages and en-
dothelial cells, but its expression was also veriﬁed in other cell
types including cells from the CNS, smooth muscle cells, ﬁbro-
blasts, cardiomyocytes, skeletal muscle, hepatocytes, and
hematopoietic stem cells [20] (Table 1).
NOX1 is highly expressed in the colon epithelia [21] and was
also detected in lower abundance in smooth muscle cells, en-
dothelial cells, uterus, placenta, pancreatic islet beta cells and
other cell types [22,23]; it is mainly localized in the plasma
membrane of caveolae, but also in early endosomes or nucleus
[24,25].
NOX3 has long been considered to be expressed in fetal tissues,
but is it now also found in the inner ear, HepG2 cells, the mouse
macrophage cell line RAW264.7, and in murine lung endothelium
[26] (Table 1).
NOX4 is widely expressed in many tissues, especially in the
kidney [27], but also in most other tissues and cells including
endothelial cells, smooth muscle cells, ﬁbroblasts and hepatocytes
[25,28–30]. In contrast to most other NOXes, NOX4 is mainly lo-
calized in the endoplasmic reticulum as well as in the outer
membrane of the nucleus [31,32]. Finally, NOX5 expression has
been detected in testis, prostate, spleen, lymph nodes, but also in
endothelial and smooth muscle cells [26] and its mainly localized
in the endoplasmic reticulum of the cell [33] (Table 1).
The two DUOX1/2 proteins are highly expressed in the thyroid,
but also in lung epithelium and gastrointestinal tract [34–36];
mainly in the endoplasmic reticulum and plasma membrane [32].
Most NOXes as well as the two DUOX members require cyto-
solic subunits for full activation. In the case of NOX2 these are the
cytosolic subunits p40phox, p47phox, p67phox as well as the
small monomeric GTPase Rac [16]. NOX1 and NOX3 can be regu-
lated by NOXO1 (p67phox homolog) and NOXA1 (p47phox
Table 1
Overview of the NOX family members (see text for details and references)
Name Subcellular
localization
Expression# Cofactors
NOX1 Caveolae membrane Colon epithelia p22phox
NOXO1Smooth muscle cells
Endothelial cellsEndosomes
Uterus NOXA1
PlacentaNucleus p47phox(?)
Pancreatic islet beta cells RAC 1
NOX2 Plasma membrane Neutrophils p22phox
Macrophages
Endothelial cells p40phox
Central nervous system
Smooth muscle cells p47phox
Fibroblasts
Phagosomes Cardiomyocytes p67phox
Skeletal muscle
Hepatocytes RAC 1/2
Hematopoietic stem cells
NOX3 Fetal tissues p22phox
NOXO1Inner ear
Hepatoblastoma cell line
HepG2
NOXA1
Murine Macrophage cell line
RAW264.7
P47phox(?)
Murine lung endothelium RAC 1
NOX4 Endoplasmic
reticulum
Kidney p22phox
Endothelial cells
Smooth muscle cells RAC 1(?)Outer nucleus
membrane Fibroblasts
Hepatocytes
NOX5a Endoplasmic
reticulum
Testis Ca2þ
Prostate
Spleen Calmodulin
Lymph nodes
Endothelial cells
Smooth muscle cells
DUOX1/2 Endoplasmic
reticulum
Thyroid Ca2þ
Plasma membrane Lung epithelium DUOX1/2
Gastrointestinal tract
a NOX5 is not present in rodents.
# Most relevant expression listed with no claim to completeness.
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and DUOXA2, respectively [26,32]. NOX4 activity seems to be in-
dependent of regulatory subunits, though a role for Rac is dis-
cussed [26] and it is mainly regulated at the expression level. In
addition to regulatory proteins, activation of NOX5 and DUOX1/2
requires calcium [17,33] and in case with NOX5 also calmodulin
[37] (Table 1). Most generated ROS in non-phagocytic cells are
mainly considered to act as second messenger molecules in several
processes including responses to nutrition [26].
2.2. Mitochondria and ROS production
Mitochondria are well known to be major ROS producers [38]
and the fraction of oxygen that is used for ROS production varies
and ranges from 0.15% to 4% [39]. Interestingly, in females mi-
tochondria produce less ROS than in males; a difference which can
be seen also in the induced levels of antioxidant enzymes in fe-
males which is largely due to the action of estrogens [40]. The
electron transport chain (ETC) within mitochondria constitutes animportant source of O2
·− formation primarily due to leaking elec-
trons from complex I (NADH-CoQ reductase) and complex III (cy-
tochrome c reductase). Thereby complex I generates O2
·− only
within the matrix, while complex III can contribute to O2
−· forma-
tion also in the intermembrane space [41]. In addition to the ETC,
also the acetyl-CoA generating enzyme pyruvate dehydrogenase
(PDH) and the Krebs cycle enzyme α-ketoglutarate dehydrogenase
(KGDH) can be sources of O2
·− [42–46]. Moreover, it was shown that
the redox enzyme p66Shc is involved in the direct reduction of
oxygen to H2O2 in the intermembrane space by using reducing
equivalents through the oxidation of cytochrome C [47].
2.3. The endoplasmic reticulum (ER) and ROS production
The endoplasmic reticulum is a place with a high rate of ROS
generation. On the one hand ER-localized ROS can be a byproduct
of ER-localized oxygenases and oxidases during oxidative protein
folding-among them endoplasmic oxidoreductin 1 (ERO1) as the
most prominent one [13,48]. On the other hand there are also ER
localized NADPH oxidases such as NOX4, NOX5, and DUOX1/2
which can contribute to ROS generation in the ER [31,33]. In ad-
dition, there is a crosstalk between enzymes of the protein folding
machinery and NADPH oxidases due to a described interaction
between PDI and NOX1/NOX4 as well as an interaction between
calmodulin and NOX5 [37,49]. Further, ER localized iron deposits
may also contribute to the pool of ROS by the formation of OH via
a Fenton reaction [50].
2.4. Lysosomes and ROS production
Lysosomes are important organelles involved in degradation of
intracellular and extracellular materials which interlinks them
with phagocytosis, endocytosis and autophagy. To operate the
degradative acidic hydrolases require a pH of about 4.8. To gen-
erate this pH, lysosomes appear to contain a redox chain which
similar to the mitochondrial ETC contributes to proton distribu-
tion. As a byproduct ROS are generated. Thereby, reduction of O2 in
three steps can give rise to OH generation [51]. Since lysosomes
are degrading iron- and copper containing macromolecules they
accumulate iron and copper. Due to the acidic and reducing lyso-
somal environment iron is mainly in the divalent, thus redox ac-
tive, state whereas lysosomal copper is usually complexed with
various thiols and is thus likely not redox-active [52]. Hence, the
presence of divalent iron further fosters generation of OH by
Fenton reactions which may affect lysosomal membrane integrity
[52].
2.5. Peroxisomes and ROS production
Peroxisomes participate in several metabolic processes, in-
cluding long-chain fatty acid β-oxidation, the oxidative part of the
pentose phosphate pathway, phospholipid biosynthesis, purine,
and polyamine metabolism as well as amino acid and polyamine
oxidation [53]. Many of the enzymes operating in these pathways
are ﬂavin-dependent oxidases [53] which produce H2O2 as a result
of their activity [54]. The major process forming H2O2 is β–oxida-
tion of fatty acids whereas a peroxisomal xanthine oxidase ap-
pears to provide not only H2O2 but also O2
·− [54]. Since H2O2 can
give rise to formation of other ROS which could damage the cells,
it needs to be degraded into per se non-reactive substances. This is
done by the enzyme catalase which converts H2O2 into O2 and H2O
[55].
2.6. Detrimental action of ROS
The harmful action of ROS is primarily due to their ability to
Fig. 2. Interrelation between ROS in signaling and cell damage. ROS generated in
cells by speciﬁc action of various enzymes appear to have a more critical role in
signaling than ROS generated as by-products of intracellular processes or due to
external toxic stimuli. ETC, electron transport chain. PDH, pyruvate dehydrogenase;
KGDH, α-ketoglutarate dehydrogenase.
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lipids (Fig. 2). Among the ROS, OH are known to mainly damage
DNA by reacting with all four bases whereas 1O2 selectively attacks
guanine [56]; O2
·− and H2O2 contribute indirectly to DNA damage
by forming OH and lipid peroxides which contribute to formation
of DNA adducts [57]. Again, most protein damage is exerted due to
the action of OH at the protein polypeptide backbone [58]; as a
consequence, further radicals such as peroxyl, alkylperoxide, or
alkoxyl radicals are formed [59].
It appears that mitochondrial DNA is more susceptible to DNAFig. 3. ROS-regulated signaling pathways. Simpliﬁed diagram representing major ROS
negatively; see text for further explanations. ROS necessary for regulation of signaling pa
the changes in cellular metabolic activity leading to altered ROS production.
DAG, diacylglycerol; ERK, extracellular signal-regulated kinase; FAK, focal adhesion kina
bound protein 2; HIF-1α, hypoxia-inducible factor-1α; IκB, inhibitor of NF-κB; IKK, IκB
phosphatase/dual speciﬁcity protein phosphatase-6; PHD, prolyl hydroxylase; PI3K, phos
kinase B; PKC, protein kinase C; PTEN, phosphatase and tensin homolog deleted on chr
kinase; SOS, son of sevenless; Shc, SHC-transforming protein; Src, sarcoma.
ETC, electron transport chain; NF-κB, nuclear factor kappa B; NOX, NADPH oxidase subu
superoxide dismutase; TCA, tricarboxylic acid.damage than nuclear DNA since it lacks histones, has only a lim-
ited repair capacity, and is ultimately exposed to mitochondrial
ROS [60]. In particular the displacement loop (D-loop) in mi-
tochondrial DNA is known as mutational hotspot and associated
with hepatocellular carcinoma [61], ovarian cancer [62], breast
cancer [63], colorectal cancer [64] and melanoma [65].
Moreover, ROS can also inﬂuence epigenetic modiﬁcations (for
review see [66]). For example, ROS can affect DNA methylation
[67] by downregulating the expression of O-6-methylguanine-
DNA methyltransferase and MLH1 (mutL homolog 1) [5]. In addi-
tion, it has been speculated that oxidative stress may also be in-
volved in the oxidation of 5-methylcytosines to 5-hydroxy-me-
thylcytosine [68]. Moreover, ROS-mediated formation of 8-oxodG
adjacent to a cytosine may prevent methylation of the latter [69].3. ROS-dependent regulation of signaling pathways
3.1. Kinase signaling and ROS
The action of ROS in various signaling networks is connected to
their physiological role but also to diseases [70–73]. Various sti-
muli, among them nutrients like fatty acids, growth factors, hor-
mones, coagulation factors, cytokines, and hypoxia were shown to
act at least partially via regulated ROS generation (Fig. 2). Thus,
aberrant generation or even degradation of ROS may limit the
signaling function of these stimuli often affecting the mitogen-
activated protein kinases (MAPK) and/or phosphatidylinositol
3-kinases (PI3K)/Akt cascades. ROS also affect pathways like pro-
tein kinase C (PKC), Wnt/β-catenin, Hedgehog, Notch [71, 74–76] in
several ways [77], and many excellent reviews have covered the
details [78,79]. We will thus concentrate only on some principlesregulated signaling pathways. ROS can inﬂuence the pathways either positively or
thways are mostly generated through speciﬁc enzymatic reactions as well as due to
se; GP, G-protein; GPCR, G-protein coupled receptor; Grb2, growth factor receptor-
kinase; MEK, MAPK/ERK kinase; MKP3, mitogen-activated protein (MAP) kinase
phatidylinositol 3-kinases; PI3P, phosphatidylinositol 3-phosphate; PKB/Akt, protein
omosome 10; Raf, ras attachement factor; Ras, Rat sarcoma; RTK, receptor tyrosine
nit; PKC, protein kinase C; PPAR, peroxisome proliferator-activated receptor; SOD,
A. Görlach et al. / Redox Biology 6 (2015) 372–385376of the best studied so far.
3.2. MAPK signaling
ROS are known to be able to activate the ERK (extracellular
signal-regulated kinase) and JNK (c-Jun NH2-terminal kinase)
MAPK cascades. Thereby they are supposed to cause autopho-
sphorylation of the epidermal growth factor receptor (EGFR) or
PDGFR in a ligand-dependent manner [80]. In addition, oxidative
modiﬁcation of Ras, a major component of the ERK1/2 cascade, at
Cys118 [81] inhibits GDP/GTP exchange, and activates Ras and the
whole cascade. Since MEK1/2 (MAPK/ERK kinase 1/2) inhibitors
can suppress ROS-mediated ERK1/2 activation [82] ROS might act
indirectly at the level of MEK1/2 or by antagonizing phosphatases
(see below) like mitogen-activated protein kinase phosphatase
(MKP3) [83] (Fig. 3).
3.3. PI3K/Akt signaling
In addition to MAPK pathway activation, growth factor protein
tyrosine kinase receptors including EGFR or PDGFR are also known
to stimulate the protein kinase B (PKB/Akt) pathway [84]; ROS,
especially H2O2 were found to activate PKB/Akt. In addition, the
tumor suppressor PTEN (phosphatase and tensin homolog deleted
on chromosome 10), a counter regulator of PKB/Akt activation was
found to be inactivated by ROS-dependent oxidation of Cys124
[85] thus enhancing PKB/Akt activation. Moreover, loss of PTEN
also causes depletion of antioxidant enzymes [86] (Fig. 3).
3.4. PKC signaling
Three major PKC subfamilies are distinguished; (i) conventional
PKC isoforms (cPKCs; α, with alternatively spliced βI/βII isoforms,
and γ); (ii) the so called novel PKCs (nPKCs, with isoforms δ, θ, ε,
and η), and (iii) atypical PKCs (aPKC; with isoforms Mζ, and ι/λ).
The cPKCs require diacylglycerol and calcium for their activity
while nPKCs can be activated by diacylglycerol independent of
calcium; aPKCs do neither require calcium nor diacylglycerol. All
are potentially susceptible to redox modiﬁcations due to their
content in cysteine residues. Indeed, some proteinkinase C (PKC)
isoforms like α, βI, and γ of cPKC, δ and ɛ of nPKC, and Mζ of aPKC,
were activated upon treatment of cells with H2O2 [87] and further
evidence points to ROS-dependent changes in a conserved cy-
steine-rich region in PKCα binding diacylglycerol [88]. However, it
appeared that the redox-dependent activation of PKC can also be
communicated in an indirect manner. In fact, the activation of
PKCδ by H2O2 was not mediated by cysteine modiﬁcation. Inter-
estingly, the H2O2-dependent increase in PKCδ activity was caused
by the tyrosine kinase Lck (a member of the Src family) which
phosphorylated a tyrosine residue between the regulatory and
catalytic domain [89]. Overall, the existence of various PKC iso-
forms with the option of a direct or indirect redox-dependent
regulation adds another layer of complexity to the understanding
of PKC regulation. This may in particular be important for those
PKCs involved in metabolic regulation; in particular isoform θ in
skeletal muscle and δ in liver can be activated by fatty acid me-
tabolites such as fatty acyl CoA and diacylglycerol. As a con-
sequence this can lead to inhibitory serine phosphorylation of
insulin receptor substrates and an attenuation of insulin signaling
[90] (Fig. 3).
3.5. Protein tyrosine phosphatases
Oxidation of catalytic cysteine residues and inactivation of
protein tyrosine phosphatases (PTP) is another ROS-dependent
regulatory mechanism of action [91]. Extracellular ligand-stimulated ROS and signal-independent ROS production can cause
PTP oxidation. In addition to classical PTPs dephosphorylating
phosphotyrosine, also dual-speciﬁcity phosphatases like MAPK
phosphatases can be inactivated by ROS-dependent oxidation [91]
(Fig. 3).4. Transcription factors and ROS
Transcription factors are among the ROS targets which can
positively or negatively respond to nutrients by changing gene
expression. Thereby the transcription factors nuclear factor kappa
B (NF-κB), nuclear factor erythroid-2-related factor-2 (Nrf2), as
well as hypoxia-inducible factor-1α (HIF-1α) and hypoxia-in-
ducible factor-2α (HIF-2α) appear to integrate the responses to
different primary stimuli at the level of ROS signaling. [92,93]
(Fig. 3). Activation/inhibition of these transcription factors can be
crucial for adaptation, survival and progression of diseases like
inﬂammation, type II diabetes, or cancer.
4.1. NF-κB signaling
The activation of NF-κB is closely linked with ROS generation
during inﬂammation and obesity [94]. ROS were found to mediate
inhibitor of NF-κBα (IκBα) kinase (IKKα and IKKβ) phosphorylation
and release of free NF-κB dimers [95]. Tumor necrosis factor α
(TNFα), a bona ﬁde NF-κB activator, was shown to mediate a redox-
dependent activation of protein kinase A [96] which subsequently
phosphorylated Ser276 on RelA (v-rel avian reticuloendotheliosis
viral oncogene homolog A). By contrast, the NF-κB member p50
was found to have reduced DNA binding activity when oxidized at
Cys62 [97,98].
4.2. Nrf2 signaling
The Nrf2 and its partner Keap1 (Kelch-like ECH-associated
protein (1) are considered as the major transcriptional regulators
in the response and defense against oxidative stress [99,100]. The
regulation of this dimer is primarily achieved by the sulfhydryl
groups within Keap1 which act as sensors for electrophiles and
oxidants [101]. In the absence of ROS binding of Keap1 promotes
proteasomal degradation of Nrf2. In the presence of ROS, cysteine
residues in Keap1, with Cys151 being the most critical, become
oxidized leading to a conformational change of Keap1, which
prevents its binding to Nrf2. In addition to oxidation, ROS can
contribute to dephosphorylation of Keap1 at Tyr141 which con-
tributes to Keap1 degradation [102]. As an overall consequence,
Nrf2 is no longer degraded and can be transported to the nucleus.
Moreover, oxidation of Cys183 in Nrf2 inhibits binding of the nu-
clear export protein CRM1 and thus promotes nuclear presence. In
the nucleus, Nrf2 heterodimerizes with a small Maf protein to
activate genes of the antioxidant response such as NAD(P)H:qui-
none oxidoreductase 1, glutathione S-transferases, cysteine-glu-
tamate exchange transporter, and multidrug resistance-associated
protein.
Interestingly, Nrf2 activating substances like quercetin, genis-
tein, curcumin and sulforaphane are often components of plants,
fruits and vegetables; therapeutics such as oltipraz, auranoﬁn and
acetaminophen; environmental agents like paraquat, and metals
as well as endogenous substances like hydrogen peroxide, NO, or
4-hydroxynonenal also activate Nrf2 signaling [103]. This some-
how may imply that an activation of the Nrf2 pathway may be of
therapeutical beneﬁt. However, Keap1 knockout mice die shortly
after birth. This ﬁnding and the rescue of this lethal phenotype in
Keap1/Nrf2 double knockout mice [104] suggests that excessive
Nrf2 activity may be detrimental for normal life. Indeed, this was
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Nrf2 pathway was beneﬁcial for tumor survival [105].
4.3. HIFα signaling
ROS play an important role in HIF signaling (for review see
[106]). Both HIF-1α and HIF-2α can be modiﬁed by ROS in a direct
and indirect manner. Direct regulation requires presence of redox
factor-1 (Ref-1) and affects transactivation of HIF-1α at Cys800 and
of HIF-2α at Cys848 [107] as well as recruitment of coactivators
such as steroid receptor coactivator-1 and transcription inter-
mediary factor 2. Another direct redox effect is oxidation of the Cys
present in the DNA-binding domain of HIF-2α, but not HIF-1α
[108]. The indirect effects of ROS are mediated via regulation of
prolyl hydroxylases (PHD), asparagine hydroxylases, redox-sensi-
tive kinases, and phosphatases (for review see [3,109]). The PHDs
hydroxylate HIF-1α and HIF-2α at critical proline residues thereby
inducing HIF degradation under normoxia. The PHDs belong to a
family of oxygen, Fe2þ , 2-oxoglutarate, and ascorbate dependent
dioxygenases (reviewed by [110]) which need a radical cycling
system to regenerate the iron after each catalytic cycle [111]. Even
though ascorbate is a key agent in the regeneration of iron, glu-
tathione could substitute it in mice deﬁcient in vitamin C synth-
esis, pointing to the importance of thiol oxidation/reduction cy-
cles. In line, a pair of cysteine residues in one of the PHDs was
described to modulate its redox sensitivity [112], again high-
lighting the possible involvement of thiol oxidation in regulating
PHD activity, though in endothelial cells subjected to hypoxia, no
variation in PHD cysteine oxidation was observed [113].
Both, HIF-1α and HIF-2α could be prevented from hydroxyla-
tion and degradation by increasing ROS generation from ER-loca-
lized NOX4 or addition of hydrogen peroxide to cells [114].
Moreover, ROS generated at the Qo site of the mitochondrial
complex III affected HIF-1α and HIF-2α regulation [115,116].
Thereby mitochondrial ROS seemed to act upstream of prolyl hy-
droxylases in regulating HIF-1α and HIF-2α [117]. From the ROS
formed, hydrogen peroxide seems to be of major importance for
HIF regulation since overexpression of glutathione peroxidase or
catalase, but not superoxide dismutase 1 or 2, prevented the hy-
poxic stabilization of HIF-1α [115,116,118]. Together, ROS appear to
constitute an important link for HIF regulation especially under
certain metabolic regimes or diseases like cancer which are asso-
ciated with altered mitochondrial activity [119].
In addition, HIFα signaling is known to undergo a crosstalk with
both PI3K/Akt and MAPK cascades where ROS and NOX enzymes
act as activators (reviewed by [120]). In line, antioxidants or NOX
inhibitors blocked signaling via PI3K/Akt to HIF-1α [121]. In ad-
dition, a number of ROS inducing substances like angiotensin-II
[122], prostaglandin E2 [123], shock waves [124], thrombin [121]
or chromium (VI) [125] contribute to HIF-1α induction via ERK1/2
which also can phosphorylate HIF-1α [120]. Further, p38 MAPKs
and the p38 upstream kinases MKK3 and MKK6 [126] were shown
to be involved in the induction of HIF-1α by thrombin [121] and
chromium (VI) [125]. In addition, these NADPH oxidases activating
substances can also induce HIF-1α mRNA levels in several cell
types [127–130]. In line, HIF-1α is a direct target gene of NFκB
[131–135], and ROS derived from NOXes or direct application of
H2O2 regulates NFκB–dependent HIF-1α transcription
[132,136,137].
Taken together, ROS are important regulators of the HIF system
and the crosstalk between ROS and HIF is an important patho-
physiological link for a wide variety of disorders.
5. Hypoxia and ROS, a paradoxical and complex relationship
Paradoxically an increased availability of lipids andcarbohydrates which is typical for a Western diet will also increase
the demand on energy synthesis in form of ATP; i.e provision of
these substances will activate usage of the mitochondrial electron
transport chain and oxygen [138]. As a result of an acute hypoxic
event a superoxide burst can occur [139]; however, hypoxia per se
seems to affect ROS production with subsequent consequences for
metabolic activity. In addition to mitochondria [119], several other
sources have been proposed to be involved in the modulation of
ROS levels under hypoxia, such as NADPH oxidases [140], or xan-
thine oxidase [141].
The variability of ROS production in response to changes in the
ambient oxygen partial pressure has been linked with the activa-
tion of the HIF α-subunits. Although controversial data exist, there
is evidence for a feedback regulation between ROS production and
the HIF pathway. However, it appears that the molecular links
between ROS, the complexes involved in oxidative phosphoryla-
tion (OXPHOS), and responses to hypoxia through the HIF pathway
are complex, less direct and may involve cell speciﬁc factors
[142,143]. This is indicated by the fact that most of the interven-
tions (if not all) on OXPHOS complexes alter not only ROS pro-
duction but also other activities, especially oxygen consumption,
oxygen redistribution [144], or metabolites taking part in the HIF-α
degrading PHD reaction such as 2-oxoglutarate or succinate (see
above). In addition to this, several molecular approaches including
overexpression of antioxidant enzymes showed a link between HIF
activation and ROS formation which was independent of the cel-
lular oxygen consumption [115–118].
Vice versa, adaptation to hypoxia through the HIF pathway has
also an effect on ROS production. Both, NOX2 and NOX4 NADPH
oxidases are HIF1 target genes [114,145] and are involved in
maintaining angiogenesis, cellular proliferation, and hypoxia-in-
duced pulmonary hypertension [114], as well as in metabolic
diseases [146,147]. In mitochondria, several HIF-dependent me-
chanisms have been described that actively contribute to reduce
OXPHOS activity under hypoxia and which have been shown (in
more or less detail) to reduce mitochondrial ROS production: re-
duction of pyruvate entry into the TCA cycle through enhanced
expression of PDK1 [148,149], PDK3 [150] or PDK4 [151,152], re-
duction of complex I activity through upregulation of NDUFA4L2
expression [153], and reduction of the activity of iron-sulfur
clusters-containing proteins (among them OXPHOS complexes) by
enhanced expression of miR-210, which represses the iron-sulfur
cluster assembly proteins ISCU1/2 [154].
In addition, HIF-1α and HIF-2α are able to affect mitochondrial
ROS production also in a negative manner. Thereby HIF-1 regulates
the hypoxic switch from COX4-1 to COX4-2 in cytochrome c oxi-
dase at complex IV, and the mitochondrial protease LON which
degrades COX4-1 [155]. In line, HIF-1α-dependent upregulation of
the tumor suppressor REDD1 decreases ROS production while loss
of REDD1 increases mitochondrial ROS [156]. HIF-2α was found to
be involved in the regulation of the SOD2 gene [157]. Together,
these mechanisms are part of a negative feedback loop for reg-
ulation of HIF-1α and HIF-2α.
Another mechanism by which hypoxic responses can be
mediated through ROS production is reversible protein cysteine
oxidation. Indeed, the recent use of a redox proteomic method, by
which reversibly oxidized protein cysteines are speciﬁcally labeled
[158], has helped to identify a number of proteins speciﬁcally
oxidized in cardiac mitochondria from mice subjected to ischemia/
reperfusion or from endothelial cells subjected to acute hypoxia
[113,159]. Thus, the identiﬁcation of reversibly oxidized proteins
by a ﬂuorescent labeling and LC-MS/MS-based approach provides
the option to explore more closely the links between acute or
chronic adaptations to hypoxia and ROS generation.
Together, it is obvious that an intricate interplay between hy-
poxia and ROS production exists and that this involves feed-
Fig. 4. Nutrients modulate ROS generation. Nutrients (free fatty acids, glucose,
amino acids) stimulate ROS production by increasing the postprandial metabolic
rate, especially in mitochondria. Further, nutrients affect ROS via signal cascades
and transcription factors that regulate expression of antioxidant/ROS-generating
enzymes.
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However, the detailed mechanisms, the timing of the responses as
well as the cell-type speciﬁc factors involved in these regulations
need still further investigations before they are completely
understood.6. Dietary fashion, ROS, and diseases
In Western societies, a signiﬁcant part of the day is spent in the
postprandial state. Postprandial oxidative stress is characterized
by an increased susceptibility of the organism towards oxidative
damage after consumption of a meal rich in lipids, proteins and/or
carbohydrates (Fig.4). Evolution of dietary patterns and lifestyle in
most developed countries support the evidence that there is a
direct relationship between diet, lifestyle and risk of certain dis-
eases including cancer; up to 35% of risk is estimated to be asso-
ciated with diet [160]. The postprandial state is characterized by
persistent substrate abundance in the circulation. Increased sub-
strate availability (like glucose), leads to an increased insulin re-
lease and also to an increment in oxidative stress as, for example, a
higher production of reactive oxygen species (ROS) [161]. The
permanent availability of oxidizable substrates at rest leads to an
enhanced mitochondrial membrane potential which, in turn, leads
to a diminished velocity in oxidative phosphorylation and, thus, a
higher possibility for electrons to “leak” from the respiratory chain
directly to molecular oxygen, resulting in ROS generation [162]
(Fig. 4). In turn, the diminished substrate utilization is accom-
panied by an increment in NADH, in both the cytosol and in mi-
tochondria. NADþ and NADH values are kept relatively constant
within a cell, and the ratio between them is considered to be a
marker of the metabolic status [163]. As such, high levels ofcellular nutrient metabolites result in ROS production and oxida-
tive stress as well as the development and progression of diseases
like obesity, non-alcoholic fatty liver diseases (NAFLD), type II
diabetes, atherosclerosis or cancer which are increasing, rapidly
reaching epidemic proportions.
In addition to the direct effect on ROS production, mainly via
the ETC, although data on NADPH oxidases also exist, nutrients
have long-term indirect effects on ROS levels via regulation of
gene expression. Thereby peroxisome proliferator-activated re-
ceptors (PPAR), liver X receptors, and sterol response element-
binding proteins, contribute to fatty acid-induced transcription
[164]. In particular PPARγ was found to promote elimination of
ROS; in a murine model of type 2 diabetes, PPARγ activation ex-
erted an antioxidant effect in vivo [165] and decreased expression
of PPARγ in morbidly obese persons was associated with the de-
crease of Cu/ZnSOD and glutaredoxin activities and an increase in
the concentration of free fatty acids after a fat meal [166]. These
features as well as the link between PPARγ, HIF-1α and activated
fatty acid uptake and glycerolipid synthesis seem to be important
for cardiac contractile dysfunction. Indeed, deletion of HIF-1α in
the heart of mice prevented hypertrophy-induced PPARγ activa-
tion, metabolic reprogramming, and contractile dysfunction [167].
In addition, fatty acids and glucose may modify the activity of
transcription factors like NF-κB, and HIF-1α [74,164] which have
antioxidant as well as ROS-generating enzyme coding genes as
targets. Therefore, transcription factors like NF-κB or HIF-1 can
respond to a macronutrient-dependent burst in ROS as well as to
the macronutrient-mediated regulation of intracellular signaling
pathways like PKC or PKB. Overall, the short-term action of mac-
ronutrients may increase ROS, but they may also cause increased
ROS scavenging via their long-term action on transcription factors.
6.1. Diets and oxidative stress
High-fat diets (HFDs) typically contain about 32–60% of calories
from fat and are commonly used to induce obesity in rodents
[168,169]. A HFD is associated with body weight increase, fat de-
position throughout various organs, a marked insulin resistance
and development of a hypoxic status in the fat depositing organs.
Before a signiﬁcant peripheral fat deposition occurs, HFDs typically
increase liver fat levels as well as hepatic insulin resistance, ele-
vation of ROS and oxidative stress [170]. In addition, the hypoxic
status becomes evident already after three days of feeding a HFD
in white adipocytes. Subsequently, HIF-1α induction contributes to
an off-set of the chronic adipose tissue inﬂammatory response
[171]. Importantly, the source of dietary fat can modify the “phe-
notype”; e.g. in comparison to fat from butter, polyunsaturated fats
present in olive and ﬁsh oil increase liver fat oxidation, reduce
liver triglyceride accumulation and liver cholesterol levels, re-
spectively [172] as well as induce expression of pro-inﬂammatory
genes [173].
An excess intake of reﬁned carbohydrates is associated with
increased weight gain, hypertriglyceridemia, ROS production and
insulin resistance in humans and animal models [174,175]. Usually,
rodent chow diets contain only 4% sucrose and less than 0.5% of
free fructose with most carbohydrates as both digestible starch
and non-digestible ﬁber from grain sources. In contrast, low-fat
puriﬁed diets can contain higher levels of sucrose and this will
depend heavily on the formula being used. It is possible to modify
puriﬁed diets by manipulating only the carbohydrates while the
essential nutrients remain at recommended levels to promote a
metabolic syndrome and to have different oxidative stress levels.
A methionine and choline-deﬁcient (MCD) diet rapidly induces
hepatic macrovesicular steatosis in rodents and leads to in-
ﬂammation, ﬁbrosis and cancer [176,177]. The MCD diet also
contains sucrose, which induces de novo lipogenesis and
Fig. 5. ROS generation and nutrient availability. Under nutrient-deﬁcient condi-
tions, as well as in the presence of nutrient excess ROS formation is above the
physiological threshold. As such, these conditions may be considered as patholo-
gical situations, with abnormally high ROS generation.
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hepatic fat accumulation, fructose was more effective than glucose
in inducing hepatocellular injury in mice fed MCD diets for 21 days
[178]. A choline-deﬁcient diet alone induces only steatosis, in-
ﬂammation and ﬁbrosis within 10 weeks [179,180], but not a
marked hepatitis, cirrhosis or hepatocellular carcinoma. A choline-
deﬁcient L-amino acid-deﬁned diet leads to the development of
typical non-alcoholic steatohepatitis (NASH), with lobular in-
ﬂammation and ﬁbrosis, a basis onwhich further hepatocarcinoma
develops [181].
6.2. Metabolic reprogramming and ROS generation
Several studies are consistent with the idea that an increased
caloric intake and/or obesity are associated with a pro-oxidant
environment and increased oxidative damage [8–12] (Fig. 5). In
line, both protein carbonylation and lipid peroxidation were in-
creased in white adipose tissue and liver of animals with high-
nutrient feeding induced obesity [182]. Increased ROS production
was shown in mitochondria isolated from skeletal muscle, kidney,
liver and adipose tissue from obese HFD fed animals [183–186]. In
addition, NADPH oxidases have also been described to contribute
to elevated ROS levels and to be upregulated in the liver in several
animal models of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis [187,188] where animals were treated with an
“high-fat” or “hypercholesterolemic” diet. Interestingly, female
mice lacking the NADPH oxidase subunit p47phox are protected
against high fat diet induced obesity [189]. Similar results have
been obtained in NOX2-deﬁcient mice [190] while NOX4 deﬁcient
mice were reported to be more obese and to have hepatic steatosis
and whole body insulin resistance [191]. The role of NOX2 in in-
sulin resistance was also corroborated in skeletal muscle. Here, a
long-term HFD increased NOX2 expression, superoxide produc-
tion, and impaired insulin signaling in skeletal muscle of wild-type
mice; these effects were not occurring in NOX2-deﬁcient mice. Cell
culture experiments with C2C12 myotubes revealed a key role for
H2O2 in mediating insulin resistance since down-regulation of
NOX2 by shRNA prevented insulin resistance induced by high
glucose or palmitate [192].
Further, increased mitochondrial ROS were found to be in-
volved in short-term HFD-induced insulin resistance in white
adipose tissue. Consuming a high-fat diet for one week impaired
insulin signaling, increased c-Jun NH2-terminal kinase phosphor-
ylation and mitochondrial ROS formation. Overexpression of hu-
man catalase in the mitochondria of these mice attenuatedmitochondrial ROS formation, inﬂammation, and maintained in-
sulin signaling. Thus, elevated mitochondrial ROS formation can
contribute to HFD-induced insulin resistance in white adipose
tissue [193]. Moreover, HIF transcription factors were shown to be
induced by NOX4-derived ROS [132,194] and lipid load [106,195].
Thus, HIFs and NOXes appear to be involved in insulin resistance,
metabolic dysfunction and inﬂammation [171,196,197] and thus
might play an important role in the concert of redox related pro-
cesses promoting the development of steatohepatitis, obesity and
type II diabetes, and aging-related diseases. Aging tissues exhibit
higher rates of ROS generation, genetic instability, and inﬂamma-
tion and in some cases telomere shortening which is accelerated
during diabetes [198,199].
Conditions of reduced glucose supply activate metabolic re-
programming that switches cells to metabolize fatty acids and
amino acids through the TCA cycle and OXPHOS; this elevates the
risk of mitochondrial oxidative damage, when compared only to
the metabolization of glucose via glycolysis (Fig. 5). Exposure of
cells in culture to free fatty acids increases ROS, suggesting that an
elevated concentration of fatty acids in the circulation may provide
an additional source of excess OXPHOS substrates through in-
creased fatty acid oxidation [200]. However, studies performed
with obese animals that develop diabetes, have shown a state of
metabolic inefﬁciency where an increase in cardiac fatty acid uti-
lization is associated with enhanced mitochondrial oxygen con-
sumption but a lower cardiac contractile capacity [201–203].
Moreover, these hearts exhibit limited ATP generation associated
with fatty acid-induced mitochondrial uncoupling and are unable
to modulate their substrate utilization in response to insulin and
fatty acid supply [201,204]. These ﬁndings suggest that mi-
tochondrial dysfunction in response to diets may arise from lipo-
toxicity or oxidative stress [205,206] rather than from changes in
glucose concentrations [204,206]. This view is supported by a
study indicating that ROS are also involved in obesity-induced
autophagy. Interestingly HFD fed transgenic mice with cardiac
overexpression of catalase did not display ROS production and
showed suppressed autophagy in the heart. In addition, the HFD
compromised myocardial geometry and function like hypertrophy,
enlarged left ventricular end systolic and diastolic diameters,
fractional shortening, cardiomyocyte contractile capacity and in-
tracellular Ca2þ were attenuated by catalase. On the molecular
level these HFD-mediated effects in the heart seemed to be
transmitted by an IKKβ-AMPK-dependent pathway which could be
inhibited by catalase [207].
By contrast, the metabolism in cancer cells is a strong example
how glucose deprivation and altered mitochondrial function con-
tribute to massive ROS production [208]. Energy production in
cancer cells is abnormally dependent on glycolysis classically best
known the “Warburg effect”. Moreover, the rapid proliferating
status dictates an increased biosynthesis which is dependent on
the availability of building blocks and reducing equivalents [209].
Therefore, cancer cells may be considered to be in a perpetually
“hungry” state. NOX1 seems to be involved in regulation of the
Warburg effect and metabolic remodeling of hepatic tumor cells
towards a sustained production of building blocks required to
maintain a high proliferative rate [210].
Moreover, cancer cells often proliferate in a hypoxic milieu,
where the adaptation is largely dependent on HIF transcription
factors regulated by NOX, and the transcriptional activation of
genes involved in various metabolic pathways, among them car-
bohydrate and fatty acid metabolism. Thereby, the role of hypoxia
and HIFs, especially HIF-1 as regulator of carbohydrate metabolism
is well established. In this respect, HIFs respond to enhanced levels
of insulin [211–213] and regulate almost every gene which is in-
volved in glucose uptake, glycogen synthesis, and glycolysis
[142,214]. Reciprocally, gluconeogenesis in liver is reduced under
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coneogenic enzyme PCK1 [215]. Moreover, lipid metabolism, in
particular in liver, appears to be more regulated by HIF-2 [216]. In
addition to the direct involvement of the HIF proteins as powerful
regulators of metabolism, recent ﬁndings indicated a cross-talk
between the insulin signaling pathway and hypoxia signaling at
the level of the HIF-regulating proline hydroxylases in liver. In
particular PHD3 was found to have a key role since its acute de-
letion improved insulin sensitivity and ameliorated diabetes by
speciﬁcally stabilizing HIF-2α [217].
Moreover, a vast majority of endogenously derived fatty acids
are synthesized in the cytosol from acetyl-CoA through a large
polyfunctional fatty acid synthetase encoded by the FASN gene.
Both the cytosolic form of acetyl-CoA synthase and FASN itself can
be induced by hypoxia [218]. However, hypoxic induction of FASN
appears to be an indirect HIF effect involving ﬁrst HIF-dependent
up-regulation of SREBP1 and an action of SREBP1 on the promoter
of FASN [218]. Further, hypoxia and the Ras regulated MAPK
pathway were also shown to regulate elongation and desaturation
of fatty acids for lipogenesis [219]. In addition to the role of hy-
poxia/HIF-1-dependent regulation of lipid metabolism, there exist
also a number of hypoxia mediated, but HIF1α-independent al-
terations of lipid metabolites and associated enzymes. For ex-
ample, a recent metabolomics approach showed that enzymatic
steps in fatty acid synthesis and the de novo synthesis of phos-
phatidylethanolamine and phosphatidylcholine were modiﬁed in
a HIF1α-dependent fashion whereas palmitate, stearate, phos-
pholipase D3 and platelet activating factor 16 were regulated in a
HIF-independent manner [220]. Overall, these ﬁndings help to
understand why an increased lipid content is a common feature of
hypoxic cancer cells [142]
Although stabilization of HIF-1α contributes to a decrease in
oxidative phosphorylation, and an initial increase in ROS produc-
tion, likely via NOX4, it also initiates a later counteracting adaptive
response e.g. by switching complex IV subunits or by increasing
the mitochondrial manganese superoxide dismutase content
[143]. These features may be important for the survival of meta-
static cancer cells since it was described that colonization of lungs
with cancer cells is dependent on reduced ROS due to HIF-1-
mediated metabolic reprogramming [221].
In line, the up-regulation of the antioxidant capacity in some
subsets of cancer stem cells appears to be associated with re-
sistance to therapy [222]. This makes exogenous agents, which are
able to modulate the susceptibility of cancer cells to oxidative
insults, interesting for anticancer strategies [223] and may, at least
in part, explain why antioxidant supplementation in cancer pa-
tients is not necessarily beneﬁcial (see below).
Recent ﬁndings from experiments where the mitochondria
targeted redox cycler mitoquinone was able to induce an autop-
hagic growth arrest in breast cancer cells associated with en-
hanced ROS levels and the initiation of an antioxidant response
underline this. Interestingly, a further knockdown of Nrf2 in these
cells potentiated the autophagy [224]. In line, more recent data
indicate that high ROS can cause autophagy, but that autophagy is
able to trigger an antioxidant feedback response by linking au-
tophagy related gene 7 (Atg7) with Keap1 and Nrf2 [225]. Overall,
this is in line with ﬁndings that a forced activation of Nrf2 has a
pro-carcinogenic function (see above) and why antioxidants are
not simply protective against cancer (see below).
Moreover, inactivating mutations in genes that promote au-
tophagy have been described in several human cancers, as well as
activation of genes that block autophagy [226]. Hyperactivation of
the Ser/Thr kinase mammalian target of rapamycin complex 1
(mTORC1) has been shown to promote breast cancer progression
through increasing autophagy [227] and aberrant mTORC1 sig-
naling has been frequently detected among common humancancers [228]. Thereby mTORC1 integrates the activation of kinase
complexes like receptor tyrosine kinases (RTKs), the PI3K, and the
mitogen activated protein kinase (MAPK) pathways which are ROS
sensitive and dictates the balance between the energetic and
anabolic demands of rapidly proliferating cancer cells [229]; hence
linking autophagy with ROS, cancer and nutrition.
6.3. Antioxidative therapeutic strategies: rather harmful than
beneﬁcial?
The association of ROS with various diseases like athero-
sclerosis, type II diabetes or cancer is known for more than three
decades [5,6,71,230] and accordingly this led to the believe that an
antioxidant supplementation would have beneﬁcial therapeutic
effects. Indeed, the ﬁrst observations were promising and an ‘an-
tioxidant hype’ emerged throughout the world. As a result, high
doses of antioxidants were examined in hundreds of studies
among them about a dozen of large randomized trials where
various combinations of the best known antioxidants except
polyphenols (so called ‘traditional antioxidants’) were included
[231]. More than 10 large-scale trials have been completed (for
review see [232]). The outcome was enigmatic. There was no
corroboration of the data derived from non-human models as well
as from observational epidemiologic studies. In particular, meta-
analyses of randomized controlled trials including tens of thou-
sands subjects found no overall association between the con-
sumption of antioxidant supplements and cancer risk [233] (for
detailed review see [232]). This ‘antioxidant paradox’ [234] is not
only limited to cancer but also reported for type II diabetes and
cardiovascular diseases [235,236].
So far it is not known why the antioxidants did not exert the
expected protective effects. The wrong type, dose, combination,
and/or duration of exposure may explain some but not all. Indeed,
in almost all large-scale trials high doses of each antioxidant were
used either alone or in limited combinations. In addition, me-
chanisms of actions have been neglected; some antioxidants in-
cluding vitamin E, vitamin C, and quercetin, can act as prooxidants
at high concentrations. Indeed, meta-analyses of the vitamin E
dose and total mortality indicated that vitamin E at high doses
Z400 IU/day) may be associated with increased mortality due to
the prooxidant effects of vitamin E at these concentrations [237].
Moreover, β–carotene can act as prooxidant when given to smo-
kers [238,239]. In line, quercetin at concentrations in the range of
1–40 mM reacts with ROS and chelates metal ions whereas at
concentrations higher than 40 mM it increases oxidative stress
[240]. Thus, antioxidant therapy may be improved if patients
would be tested for subclinical deﬁciencies of antioxidants before
such a therapy is initiated. In addition, the large clinical trials did
not test for compliance like the EPIC Norfolk clinical trial in which
certain antioxidant levels were measured in plasma and where
signiﬁcant improvement of various parameters could be reported.
For example, parental administration of vitamin C was highly
beneﬁcial in many different disease conditions [241].
However, the beneﬁcial effects of antioxidant-rich food at least
with respect to cancer are widely reported [242–244]; but these
beneﬁts are achieved by the diet itself and not by supplementation
[245]. Moreover, the dietary intake involves low doses of various
antioxidants and not high doses of a single antioxidant. In line,
while high doses of single antioxidants were shown to be harmful
in smokers, two antioxidant-rich diets were found to be safe in a
randomised controlled trial in male smokers [246]. Overall, this
suggests that antioxidant therapies are not hopeless but to ﬁnd an
optimal way more research on ROS, antioxidants and nutrition in
line with large multicenter trials are necessary.
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ROS have likely evolved together with the appearance of oxy-
gen on earth and the evolution of aerobic living cells. At the same
time aerobic living cells developed systems allowing to use ROS in
signaling and to protect themselves from their harmful effects.
Within these systems components need to be maintained and
provision of certain substances through the diet is a prerequisite.
Although the human genome seems to be quite stable for the last
ten thousand years (spontaneous mutation rate is appr. 0.5% per
million years [247]), dietary fashion, food amount and composition
has changed within the last 60–100 years; at least in the Western
world. In addition to the increase in the caloric intake, also the
decreased energy expenditure as well as alcoholism and smoking
contribute to generation of more ROS than needed. As a con-
sequence the antioxidant capability is confronted with various
problems and not always able to maintain redox homeostasis,
which is, at least in part, associated with the occurrence of several
chronic diseases like adiposity, atherosclerosis, type II diabetes,
and cancer. In addition, the little or no beneﬁt evidence from the
large scale studies with antioxidant supplementation demands to
further improve the knowledge about the interconnection of ROS
with nutrition and diseases indicating that the associated health
problems are not yet solved.Conﬂict of interest statement
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